MAM
PTCT icon

Marquette Asset Management’s PTC Therapeutics PTCT Stock Holding History

Marquette Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-26
Closed -$2.12K – 888
2026
Q2 		$2.12K Hold
26
– – ﹤0.01% 593
2026
Q1 		$1.77K Buy
26
+19
+271% +$1.34K ﹤0.01% 571
2025
Q4 		$532 Buy
+7
New +$509 ﹤0.01% 645

Other funds holding PTCT

JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.15B AUM 43.46% 1-Year Est. Return
SA
Sacks & Associates Warren, New Jersey $143M AUM 17.48% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Marquette Asset Management's PTCT Position: Q3 2026 in Review

Marquette Asset Management sold out of PTC Therapeutics (PTCT) in Q3 2026, closing a stake of 26 shares — an estimated $2.12K sold.

Marquette Asset Management first reported a position in PTCT in Q4 2025 and held it in 3 quarters. The position peaked at $2.12K in Q2 2026. 8 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • Marquette Asset Management reported no remaining PTC Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Marquette Asset Management sold 26 PTC Therapeutics shares in Q3 2026, an estimated $2.12K.
  • Marquette Asset Management first reported a position in PTC Therapeutics in Q4 2025 and held it in 3 quarters.
  • Marquette Asset Management's PTC Therapeutics position peaked at $2.12K in Q2 2026.
  • 8 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on Marquette Asset Management's 13F filing for Q3 2026, filed 9 Oct 2026.